A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.

ABSTRACT:

Background

The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving, particularly for patients exposed or refractory to lenalidomide. With the aim of evaluating the relative efficacy of lenalidomide-free regimens as second-line treatment options, an updated network meta-analysis, incorporating phase II/III randomized controlled trials, has been conducted.

Materials and methods

A systematic literature search identified eight eligible trials comprising 3952 patients. The primary outcome was progression-free survival (PFS), analyzed through Bayesian and frequentist approaches.

Results

Our findings indicate that belantamab mafodotin, bortezomib, and dexamethasone (BVd) combination is the most effective regimen for both lenalidomide-expos

SUBMITTER: Martino EA 

PROVIDER: S-EPMC12281279 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature